Newly diagnosed amyotrophic lateral sclerosis (ALS) patients often experience poor sleep quality due to symptoms of depression and difficulty turning in bed, a patient survey shows. The study, “Poor Sleep Quality in Patients With Amyotrophic Lateral Sclerosis at the Time of Diagnosis,” was published in the Journal…
Project ALS and Columbia University are launching a new platform with a goal of discovering more useful treatments for amyotrophic lateral sclerosis (ALS) patients, and pushing the most promising candidates to clinical trials. Core, as it…
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that affects motor neurons, the nerve cells responsible for controlling movement. In about 10% of cases, ALS is familial, meaning the disease does or did affect more than one person in the same family. Most patients, in contrast, have…
About 90% of cases of amyotrophic lateral sclerosis (ALS) — the progressive neurological disorder associated with the loss of motor neurons, the nerve cells that control movement — occur in patients with no family history of the disease. These cases are known as sporadic ALS, and occur randomly.
Aquestive’s new drug application for Exservan — an investigational oral film of riluzole to be used as an add-on therapy for amyotrophic lateral sclerosis (ALS) — has been accepted by the U.S. Food…
“If anything can go wrong, it will.” — Murphy’s Law That adage could be the ALS anthem. From the onset of mysterious symptoms to the serpentine-like diagnostic process and worst-case outcome, and by watching your body unfailingly obey his maxim, the prophet Murphy is seemingly ever-present. The…
The U.S. Food and Drug Administration approved MediciNova’s plans for a pivotal Phase 2b/3 clinical trial that will explore the potential of ibudilast (MN-166) in patients with amyotrophic lateral sclerosis (ALS). Pending the success of the trial, the company hopes the collected clinical data will support the…
Recently, I attended an “Ask the Experts” educational seminar sponsored by my local chapter of the ALS Association. It’s an annual event that presents current information on ALS-related topics and allows attendees to exchange ideas with fellow ALS patients. This year’s theme was “ALS clinical trials…
Damaged activity of RNA-binding proteins (RBPs) associated with amyotrophic lateral sclerosis (ALS) can be alleviated by inducing autophagy, a process where cells degrade or recycle components that are damaged or no longer needed, a study says. The study, “FUS pathology in ALS is linked to alterations in multiple ALS-associated proteins…
The most common genetic cause of amyotrophic lateral sclerosis (ALS) disrupts the shape and workings of a compartment inside a cell’s nucleus, researchers report, detailing a discovery that helps to explain how this mutation prompts cell death in ALS. Abnormalities resulting from this mutation, specifically the length of the…
